This page is part of the Evidence Based Medicine on FHIR Implementation Guide (v1.0.0-ballot: STU1 Ballot 1) based on FHIR (HL7® FHIR® Standard) v5.0.0. . For a full list of available versions, see the Directory of published versions
Active as of 2022-05-28 |
<EvidenceVariable xmlns="http://hl7.org/fhir">
<id value="32143"/>
<meta>
<versionId value="13"/>
<lastUpdated value="2023-12-06T21:24:16.455Z"/>
<profile
value="http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"/>
</meta>
<text>
<status value="extensions"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p><b>Generated Narrative: EvidenceVariable</b><a name="32143"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Resource EvidenceVariable "32143" Version "13" Updated "2023-12-06 21:24:16+0000" </p><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-variable-definition.html">VariableDefinition</a></p></div><p><b>EvidenceVariableDefinition</b>: OutcomeDefinition: American Diabetes Association composite triple end point for metabolic control</p><p><b>StructureDefinition Work Group</b>: cds</p><p><b>url</b>: <code>https://fevir.net/resources/EvidenceVariable/32143</code></p><p><b>identifier</b>: FEvIR Object Identifier: 32143</p><p><b>version</b>: 1.0.0-ballot</p><p><b>name</b>: OutcomeVariable_American_Diabetes_Association_composite_triple_end_point_for_metabolic_control_at_5_years</p><p><b>title</b>: OutcomeVariable: American Diabetes Association composite triple end point for metabolic control at 5 years</p><p><b>status</b>: active</p><p><b>date</b>: 2022-05-28 12:16:43+0000</p><p><b>publisher</b>: HL7 International / Clinical Decision Support</p><p><b>contact</b>: HL7 International / Clinical Decision Support: <a href="http://www.hl7.org/Special/committees/dss">http://www.hl7.org/Special/committees/dss</a></p><p><b>description</b>: The American Diabetes Association composite triple end point of hemoglobin A1c less than 7.0%, low-density lipoprotein cholesterol less than 100 mg/dL, and systolic blood pressure less than 130 mm Hg at 5 years</p><p><b>copyright</b>: https://creativecommons.org/licenses/by-nc-sa/4.0/</p><p><b>author</b>: Brian S. Alper: </p><h3>RelatedArtifacts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Citation</b></td></tr><tr><td style="display: none">*</td><td>cite-as</td><td>OutcomeVariable: American Diabetes Association composite triple end point for metabolic control at 5 years [EvidenceVariable]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 32143. Revised 2022-05-28. Available at: https://fevir.net/resources/EvidenceVariable/32143. Computable resource at: https://fevir.net/resources/EvidenceVariable/32143.</td></tr></table><p><b>actual</b>: true</p><p><b>handling</b>: dichotomous</p></div>
</text>
<extension
url="http://hl7.org/fhir/uv/ebm/StructureDefinition/evidence-variable-definition">
<valueCodeableReference>
<reference>🔗
<reference value="Group/172480"/>
<type value="Group"/>
<display
value="OutcomeDefinition: American Diabetes Association composite triple end point for metabolic control"/>
</reference>
</valueCodeableReference>
</extension>
<extension
url="http://hl7.org/fhir/StructureDefinition/structuredefinition-wg">
<valueCode value="cds"/>
</extension>
<url value="https://fevir.net/resources/EvidenceVariable/32143"/>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="ACSN"/>
<display value="Accession ID"/>
</coding>
<text value="FEvIR Object Identifier"/>
</type>
<system value="https://fevir.net"/>
<value value="32143"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<version value="1.0.0-ballot"/>
<name
value="OutcomeVariable_American_Diabetes_Association_composite_triple_end_point_for_metabolic_control_at_5_years"/>
<title
value="OutcomeVariable: American Diabetes Association composite triple end point for metabolic control at 5 years"/>
<status value="active"/>
<date value="2022-05-28T12:16:43.370Z"/>
<publisher value="HL7 International / Clinical Decision Support"/>
<contact>
<name value="HL7 International / Clinical Decision Support"/>
<telecom>
<system value="url"/>
<value value="http://www.hl7.org/Special/committees/dss"/>
</telecom>
</contact>
<description
value="The American Diabetes Association composite triple end point of hemoglobin A1c less than 7.0%, low-density lipoprotein cholesterol less than 100 mg/dL, and systolic blood pressure less than 130 mm Hg at 5 years"/>
<copyright value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
<author>
<name value="Brian S. Alper"/>
</author>
<relatedArtifact>
<type value="cite-as"/>
<citation
value="OutcomeVariable: American Diabetes Association composite triple end point for metabolic control at 5 years [EvidenceVariable]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 32143. Revised 2022-05-28. Available at: https://fevir.net/resources/EvidenceVariable/32143. Computable resource at: https://fevir.net/resources/EvidenceVariable/32143."/>
</relatedArtifact>
<actual value="true"/>
<handling value="dichotomous"/>
</EvidenceVariable>
IG © 2022+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#1.0.0-ballot based on FHIR 5.0.0. Generated 2023-12-17
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change